Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $30.00

Definium Therapeutics (NASDAQ:DFTX) had its target price hoisted by Leerink Partners from $23.00 to $30.00 in a report published on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other equities research analysts have also issued reports about the company. HC Wainwright upped their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Royal Bank Of Canada upped their price objective on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Finally, Stifel Nicolaus set a $30.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Definium Therapeutics currently has an average rating of “Buy” and a consensus target price of $38.00.

Definium Therapeutics Trading Down 3.4%

Definium Therapeutics stock opened at $22.48 on Wednesday. Definium Therapeutics has a 12 month low of $6.03 and a 12 month high of $26.25. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -10.55 and a beta of 2.44. The business has a 50 day moving average price of $19.28 and a two-hundred day moving average price of $15.54. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Stoneridge Investment Partners LLC increased its holdings in Definium Therapeutics by 7.5% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock valued at $136,000 after purchasing an additional 804 shares in the last quarter. Cerity Partners LLC increased its holdings in Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after purchasing an additional 1,165 shares in the last quarter. Creative Planning increased its holdings in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after purchasing an additional 1,655 shares in the last quarter. Rathbones Group PLC increased its holdings in Definium Therapeutics by 7.1% during the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock valued at $356,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Bay Rivers Group increased its holdings in Definium Therapeutics by 14.3% during the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares in the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.